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Drug-resistant tuberculosis (TB), especially multidrug-resistant TB (MDR-TB), poses a
threat to public health. While standard surveillance focuses on Rifampicin and/or Isoniazid
resistance, little is known about other resistance patterns. This study aims to identify pre-
dominant drug resistance (DR) patterns in Germany and risk factors associated with them in
order to inform diagnostic and treatment strategies.
Methods
Case-based TB surveillance data notified in Germany from 2008–2017 were utilized to
investigate DR and MDR-TB patterns for Isoniazid (H), Rifampicin (R), Pyrazinamide (Z),
Ethambutol (E), and Streptomycin (S). Predominant patterns were further analyzed strati-
fied by sex, age, country of birth, prior TB, and disease site. Multivariable logistic regression
was conducted to determine risk factors associated with any resistance, MDR-TB, and com-
plete HRZES resistance.
Results
26,228 cases with complete DST results were included in the study, among which 3,324
cases had any DR (12.7%). Four patterns were predominant, representing about ¾ of all
cases with any resistance (S: 814 [3.1%]; H: 768 [2.9%]; HS: 552 [2.1%]; Z: 412 [1.6%]).
High proportions of S and H resistances were found among both German and foreign-born
populations, especially those born in Eastern Europe, and were unexpectedly high among
children (H: 4.3%; S: 4.6%). Foreign-born cases had significantly higher proportion of any
resistance (16.0%) and MDR-TB (3.3%) compared to German-born cases (8.3% and
0.6%). Of 556 MDR-TB cases, 39.2% showed complete HRZES resistance. Logistic regres-
sion revealed having prior TB and being foreign-born as consistently strong risk factors for
any DR, MDR-TB, and complete HRZES resistance.
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Conclusions
DR patterns observed in Germany, particularly for MDR-TB were more complex than
expected, highlighting the fact that detailed drug-testing results are crucial before incorpo-
rating HRZES drugs in MDR-TB treatment. Furthermore, the relatively high rate of H-resis-
tance in Germany provides strong rationale against the use of only H-based preventive
therapy for LTBI.
Introduction
Tuberculosis (TB) is the ninth leading cause of death worldwide and the leading cause of death
from a single infectious agent, exceeding even HIV/AIDS [1]. The World Health Organization
(WHO) estimates that in 2017, approximately 10 million people were diagnosed with TB and
1.6 million people died due to the disease [1]. About one quarter of the world’s population is
further estimated to be latently infected [1]. As a result, TB control is a top priority on the
global health agenda. One of the WHO´s End TB strategy targets aims to reduce the global
incidence to<100 TB cases per million by 2035 [2]. The WHO has also developed a Frame-
work for low-incidence countries [3], asking them to reach pre-elimination phase (<10 cases
per million) by 2035 and elimination (<1 case per million) by 2050 or earlier [3]. One of the
biggest obstacles in achieving TB elimination is the emergence of drug resistance [1]. In 2017,
558,000 cases were estimated to be resistant to Rifampicin (R), the most effective first-line
anti-tuberculosis drug [1], with 82% suffering from multidrug-resistant TB (MDR-TB) [1],
which is defined as the resistance to at least Rifampicin and Isoniazid, another potent anti-TB
drug [1]. Tackling MDR-TB is an especially important cornerstone of the increasingly urgent
global fight against antimicrobial resistance (AMR) [4].
A number of experts have suggested the lack of political commitment, inadequate health-
care systems, poor disease management, unsound drug policies, and a long-standing neglect in
research as having facilitated the global rise in drug-resistant TB and MDR-TB [5, 6]; the
increase in MDR-TB is especially concerning due to its prolonged, difficult, and potentially
toxic treatment. In 2016, in the European Economic Region, almost two-thirds of MDR-TB
cases were notified as having failed, defaulted, or died during treatment [7]. Inadequate
MDR-TB treatment facilitates the development of extensively drug resistant TB (MDR-TB
plus resistance against one Fluoroquinolone and one injectable; XDR TB) and paves the way
for further transmission [5]. Thus, resistant, and especially MDR-TB, pose an immense threat
to public health [8].
With almost 20% of R-resistant (RR) or MDR-TB cases in 2016, the WHO European
Region has the highest regional burden of MDR-TB in the world [6, 9]. In 2016 alone, 19% of
new TB cases and 55% of previously treated cases were diagnosed with RR/MDR-TB, which is
considerably higher than the global average [10]. Eastern European countries present the high-
est resistance rates in Europe [6, 11]. Studies have further shown that MDR-TB strains have
been imported into and transmitted throughout the EU/EEA region [5, 11–14].
Germany represents a low TB incidence country, with 5,486 cases in 2017 and a notified
incidence of 6.7/100,000 [15]. In the past 10 years, the drug resistance trend in Germany has
fluctuated slightly, peaking in 2013, but has remained overall stable at 2–3%. In 2017, drug
resistance against at least one of the five standard anti-TB drugs H, R, Pyrazinamide (Z), Eth-
ambutol (E) and Streptomycin (S) was notified in 431 (11.9%) cases with available information
(information needed be available for at least H and R resistances). MDR-TB was reported in
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109 cases (3.0%), of which 4 were reported as having XDR-TB [15]. Even within the context of
Germany’s low TB incidence, however, it is important to remain attentive to epidemiological
changes in drug-resistant TB in order to inform clinical decision-making on appropriate drug
regimens [16].
As TB treatment has shifted from standardized to more individualized approaches [17–19]
information on drug resistance patterns within the population has become ever more relevant
and important. Furthermore, due to the high prevalence of MDR-TB among R-resistant cases,
R resistance is considered as surrogate for MDR-TB and amongst the WHO-endorsed rapid
drug susceptibility testing (DST) tools, one of the most frequently utilized tools tests only for R
resistance [20–23]. However, this approach is questioned by some experts and, hence, addi-
tional DST for H, especially in low-incidence settings, is recommended [24, 25]. Here too,
information on drug resistance patterns is crucial to inform the utilization of different resis-
tance diagnostic methods.
To our knowledge, with the exception of one study conducted by the European Centre for
Disease Prevention and Control, covering a period from 2007 to 2012, there is currently no
analysis available on drug resistance patterns in low TB incidence countries in Europe, such as
Germany [16]. Other studies who have addressed this question either limited their analysis to
certain population groups [26–28] or were conducted using surveillance data from high TB
incidence countries with very different TB epidemiology [29–31]. As a result, this study aims
to analyze German national TB surveillance data for the predominant drug resistance patterns
for the five standard anti-TB drugs (Isoniazid—H, Rifampicin—R, Pyrazinamide—Z, Etham-
butol–E, Streptomycin–S; HRZES) and the factors associated with them, in order to inform
diagnostic and treatment strategies for TB patients in low incidence countries such as Ger-
many. The objectives of this study are to determine (i) frequency and distribution of drug
resistance patterns over a 10-year period and (ii) demographic factors associated with specific
drug resistance patterns.
Methods
Data source and collection
TB is a notifiable disease in Germany [32]. District health authorities report, via their respec-
tive state health departments case-based data electronically to the national surveillance data-
base (SurvNet@rki, [33]) of the Robert Koch Institute (RKI). The data comprises of, among
others, information on case demographics, site of disease, prior TB disease, bacteriological
findings, DST results, and treatment outcome.
Case inclusion and definitions
For study inclusion, a case had to meet the following criteria: fulfil the RKI reference case defi-
nition for active TB disease [34], be notified between the years 2008 to 2017, be culture posi-
tive, and have been tested for all five HRZES drugs and have DST results available. The cut-off
date for the data extraction was March 1st, 2018. As S was considered and used as a first-line
TB drug until 2011 covered by the study period, it was included in the analyses to reflect drug
resistance dynamics in Germany. Z was also included, despite inconsistent international
guidelines regarding the reliability and quality assurance of its DST [35, 36] as interlaboratory
tests in Germany revealed good performance; Z has become increasingly important in newer
therapy regimens [37, 38]. Information on second-line drugs could not be included in this
analysis due to insufficient data completeness.
Cases <15 years were categorized as children; cases between 15 and 59 years were catego-
rized as adults, and cases > = 60 years as elderly. Any drug resistance was defined as resistance
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against at least one of the HRZES drugs, any R and any H resistance was defined as resistance
to at least R or H, respectively. MDR-TB was defined as being resistant against at least H and
R. A case was considered a previous case, when a prior diagnosis of TB disease was notified.
Data analysis
For the purposes of this study, the following variables were extracted from the national surveil-
lance database: age, sex, country of birth, prior TB diagnosis (yes/no; used as surrogate for
prior treatment due to a much higher level of data completeness), main site of disease (pulmo-
nary vs. extrapulmonary), presence of MDR-TB (yes/no), individual DST results for HRZES
(resistant vs. susceptible). For children <15 years of age, country of birth (born in Germany
vs. born outside Germany) of the father and/or mother were also extracted.
Drug resistance patterns and their distribution were first analyzed descriptively and pre-
sented as case counts and proportions stratified by sex, age-group, country of birth, prior TB,
and site of disease. Trends in HRZES monoresistances and MDR-TB, including MDR-TB with
additional resistances to first line drugs, were analyzed using the Chi2 test for linear trends.
For all other analyses, data were pooled over the entire study period. Case counts were com-
pared using the Chi2 test and the corresponding p-values specified.
Further exploratory analysis was then conducted using univariable logistic regression.
Finally, multivariable logistic regression analyses were performed to determine the association
between age, sex, country of birth, previous TB, and site of disease (independent variables) and
the presence of any resistance, MDR-TB, and resistance against all five drugs (dependent vari-
ables). The variable age was categorized into the following three groups before inclusion into
the models: children (<15 years), adults (15–59 years) and elderly (60+ years). This was con-
ducted in order to elucidate the expected differences in drug resistance patterns between the
different age groups due to birth cohort effects as well as effect modification by age. Cases with
missing values for any of the included variables were excluded from the analyses. A p-value
of<0.01 was considered significant for the descriptive analyses, while 95% confidence inter-
vals were calculated for the logistic regression analyses. All data were analyzed in RStudio Ver-
sion 1.0.153 [39]. All data were collected in accordance with the German ‘Protection against
Infection Act’ (‘Infektionsschutzgesetz’) and data protection guidelines were strictly followed.
Informed consent was deemed not necessary as data were fully anonymized before analysis.
Results
Between 2008 and 2017, 48,044 active TB cases that met the RKI reference definition were
notified in Germany. 41,932 cases (87.3%) had a culture result available, of which 34,141 were
culture positive (81.4%). Of these, DST results were available for all 5 drugs (HRZES) for
26,228 cases or 76.8% (Fig 1). These 26,228 cases were considered to be the final study
population.
For those with available information, foreign-born cases comprised 57.1% of all included
cases. Similarly, for those with available information, the median age of the entire study popu-
lation was 45 years and 63.2% were male. Median age among foreign-born cases was 35 years
and 62.3% were male (German-born: 58 years and 64.7%, respectively). 12.5% of all cases with
information on prior diagnosis were previously diagnosed with TB. Further case characteris-
tics are shown in Table 1.
Trends in drug resistance over time
The pooled national data revealed an overall proportion of any drug resistance of 3,324/26,228
(12.7%) in Germany (Fig 1). No significant overall changes could be observed for H, R, Z, and
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E monoresistance rates between 2008 and 2017 (p>0.01 for all; Fig 2), while S-monoresistance
rates showed a significantly increasing trend over time (p<0.01, respectively) (Fig 2). However,
the increasing trend was present until 2016 and the S-monoresistance rates declined in 2017.
Overall, MDR-TB was found in 2.1% of cases in Germany but showed a significantly increas-
ing trend over the study period (p<0.01; Figs 2 and 3). MDR-TB accounted for 40/2,891
(1.4%) TB cases in 2008 and for 47/1830 (2.6%) in 2017. Among MDR-TB cases, no clear
trend was observed in the rates of resistance to all five drugs, but a remarkable increase from
2012 (10/54 (18.5%) of MDR-TB cases) to 2013 (46/87, 52.9% of MDR-TB cases) (Fig 3).
Resistance patterns overall
Among the 26,228 cases with complete DST results, 3,324 (12.7%) were resistant to at least one
of the five drugs (any resistance) (Fig 1). Out of 31 possible resistance patterns, 28 could be
identified in the surveillance data, of which 4 patterns accounted for more than ¾ of all drug
resistant cases (for S: 24.5%; H: 23.1%, HS: 16.6%; Z: 12.4%; Fig 1). Three possible patterns
were not represented (RZE, RZS and ZES) and one pattern was only found once (HZE). Over-
all, 556 (2.1%) cases had MDR-TB, of which 218/556 (39.2%) showed resistance against all five
drugs, 143/556 (25.7%) were resistant to four drugs, 141/556 (25.4%) to three drugs and 54/
556 (9.7%) were resistant to only H and R (Fig 1).
Fig 1. Flow chart describing case selection process and observed predominant drug resistance patterns for the five anti-TB drugs, and drug resistant patterns in
MDR-TB cases, Germany 2008–2017: Isoniazid/H, Rifampicin/R, Pyrazinamide/Z, Ethambutol/E, and Streptomycin/S; DST = drug susceptibility testing.
https://doi.org/10.1371/journal.pone.0217597.g001
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Any resistance to R was present in 643/3,324 (19.3%) cases and 556 (86.5%) of them had MDR-
TB, i.e. additional resistance to at least H. 87 R resistant cases had no accompanying H resistance
(Table 2), accounting for 0.3% of all included cases and 13.5% of all cases with any R resistance.
Drug resistance according to sex
Within the study population, 9,627/26,228 (36.8%) cases were female and 16,556/26,228
(63.2%) were male (Table 1). 2,033/16,556 (12.3%) males and 1,280/9,627 (13.3%) females
diagnosed with TB had any resistance. No significant difference between sexes could be
observed with regard to any resistance, H monoresistance, combined resistance to HS and
MDR-TB (p>0.01 for all, data not shown). However, females had a significantly higher pro-
portion of Z-monoresistance (male: 222/2,033, 10.9%; female: 190/1,280, 14.8%, p<0.01),
while males had a significantly higher proportion of S-monoresistance (male: 534/2,033,
26.7%; female: 279/1,280, 21.8%, p<0.01).
Drug resistance according to country of birth
When examining the resistance patterns by country of birth, cases born in Russia, Somalia,
Kazakhstan, Turkey, India, Vietnam, Romania, Eritrea, Pakistan and Afghanistan accounted
Table 1. Characteristics of study population: All culture-positive TB cases with DST results for HRZES by drug resistance patterns in Germany, 2008–2017.
Characteristics Total number of cases Pan-susceptible Monoresistant MDR TB Others
N % N % N % N % N %
Total 26, 228 22,904 2, 080 556 688
Sex
(n = 26,183)
Female 9,627 36.8% 8,347 36.5% 810 39.1% 202 36.3% 268 39.2%
Male 16,556 63.2% 14,523 63.5% 1,263 60.9% 354 63.7% 416 60.8%
Unknown 45 34 7 0 4
Age groups [years]
(n = 26,226)
0–14 588 2.2% 484 2.1% 65 3.1% 14 2.5% 25 3.6%
15–39 10,534 40.2% 8,948 39.1% 935 45.0% 341 61.3% 310 45.1%
40–59 7,173 27.4% 6,229 27.2% 549 26.4% 155 27.9% 240 34.9%
60+ 7,931 30.2% 7,242 31.6% 530 25.5% 46 8.3% 113 16.4%
Unknown 2 1 1 0 0
Country of birth
(n = 25,569)
Foreign 14,600 57.1% 12,263 54.9% 1,333 65.7% 478 87.2% 526 78.3%
Germany 10,969 42.9% 10,056 45.1% 697 34.3% 70 12.8% 146 21.7%
Unknown 659 585 50 8 16
Previous TB
(n = 22,555)
No 19,735 87.5% 17,432 88.3% 1,529 86.4% 281 60.2% 493 84.7%
Yes 2,820 12.5% 2,304 11.7% 241 13.6% 186 39.8% 89 15.3%
Unknown 3,673 3,168 310 89 106
Site of disease
(n = 26,195)
Pulmonary 21,254 81.1% 18,608 81.3% 1,591 76.7% 493 88.8% 562 81.7%
Extra-pulmonary 4,941 18.9% 4,270 18.7% 483 23.3% 62 11.2% 126 18.3%
Unknown 33 26 6 1 0
https://doi.org/10.1371/journal.pone.0217597.t001
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for the highest numbers of drug resistant cases. Cases born in Russia, Kazakhstan and Vietnam
presented the highest proportions of any drug resistance with 33.2%, 28.2%, and 26.7%,
respectively. For MDR-TB, once again cases born in Russia (14.1%) and Kazakhstan (8.2%)
presented the highest proportions, followed by Somalia (3.8%). Because of the recent shift in
country of origin of migrants in Germany from predominantly Eastern European countries
towards countries from the Horn of Africa and the Middle East, country rankings were also
analyzed in two 5-year timespans (208–2012 and 2013–2017).Between 2008 and 2012, Turkey,
Russia, and Kazakhstan, had the three highest absolute shares of resistances in Germany. How-
ever, between 2013 and 2017, African countries became more dominant and cases born in
Somalia and Eritrea, having the top two absolute shares of resistances, with Romania ranked
third. Table 3 shows the overall proportions of any drug resistance, any H-resistance, any R-
resistance, and MDR-TB for the top 10 countries of birth from 2008 to 2017.
Resistance patterns according to age and country of birth
Overall, German-born cases had a significantly lower proportion of any resistance than for-
eign-born patients (German-born: 913/10,969, 8.3%, Foreign-born: 2,337/14,600 16.0%,
p<0.01). In German-born cases, drug resistance was mainly attributable to monoresistances,
especially H (228/913, 25.0%) and S (236/913, 25.8%; Table 4). Moreover, 96 German-born
cases had any resistance to R (0.9%), among which 70 (72.9%) had MDR-TB and 20 (20.8%)
had R monoresistance. In foreign-born cases, drug resistance was attributable to high propor-
tions of MDR-TB (478/2,337, 20.5%), H (521/2,337, 22.3%) and S (561/2,337, 24.0%) monore-
sistances. 536 (3.7%) foreign-born cases had any R-resistance of which 478 (89.2%) cases had
Fig 2. Trends in monoresistant TB and MDR-TB notifications between 2008 and 2017 in Germany.
https://doi.org/10.1371/journal.pone.0217597.g002
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MDR-TB and 48 (9.0%) cases had R monoresistance. Foreign-born cases also had higher pro-
portions of combined resistance against HS (foreign-born: 429/2,337, 18.4%, German-born:
109/913. 11.9%; p<0.01), especially in the age groups 40–59 years (Foreign-born: 150/633,
23.7%; German-born: 45/287, 15.7%; p<0.01) and 60+ years, with a notable difference in those
aged 60+ (German-born: 28/395, 4.6%; foreign-born: 56/283, 19.8%; p<0.01). However, cases
born in Germany had a higher proportion of Z-monoresistance (German-born: 206/913,
22.6%; foreign-born:197/2,337 8.4%, p<0.01), especially among those aged 60+ (German-
born: 145/395, 36.7%; Foreign-born: 44/283, 15.5%, p<0.01).
Both groups showed a decreasing MDR-TB trend with increasing age (p<0.01 for both).
However, cases born outside Germany were more affected by MDR-TB with 478/14,600
(3.3%) compared to 70/10,969 (0.6%) in German-born cases (p<0.01). For cases with
MDR-TB, regardless of their origin, resistance against all 5 drugs was the most common pat-
tern, accounting for 23/70 (32.9%) of MDR-TB cases born in Germany and 191/478 (40.0%) of
cases born outside Germany (Table 5). Resistance against only H and R accounted for 10/70
(14.3%) of all MDR-TB cases among German-born cases and for 44/478 (9.2%) of cases born
outside Germany.
Drug resistance according to prior TB
Overall, 2,820/22,555 (12.5%) of all cases reported having prior TB diagnosis, while the major-
ity (19,735/22,555, 87.5%) reported not having a prior disease. Cases with prior TB had a sig-
nificantly higher proportion of any resistance, with 516/2,820 (18.3%) in comparison to 2.303/
19,735 (11.7%) among new cases (p<0.01). While new cases presented significantly higher
Fig 3. Rate of pan-resistance to first-line drugs among MDR-TB notifications.
https://doi.org/10.1371/journal.pone.0217597.g003
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proportions of S (new cases: 614/2,303, 26.7%; previous cases: 81/516, 15.7%; p<0.01) and Z
monoresistance (new cases: 300/2,303, 13.0%; previous cases: 43/516, 8.3%; p<0.01), previous
cases had a higher MDR-TB proportion with 186/2,820 (6.6%) in comparison to 281/19,735
(1.4%, p<0.01) for new cases. Among MDR-TB cases, resistance against all five drugs (HRZES)
was once again the predominant pattern for both groups, accounting for 92/281 (32.7%) of new
and 89/186 (47.8%) of previous MDR-TB cases. After further stratification for country of birth,
only foreign-born cases still showed significant differences in the proportions of any resistance
and MDR-TB between new and previous cases. Specifically, 1,553/10,630 (14.6%) of foreign-
born new cases and 367/1,352 (27.1%) of previous cases had any resistance and 224/10,630
(2.1%) of foreign-born new cases and 171/1,352 (12.6%) of previous cases had MDR-TB.
Drug resistance according to site of disease
Within the study population 21,254/26,195 cases (81.1%) had pulmonary TB and 4,941/26,195
(18.9%) cases had extrapulmonary TB. For any resistance, there was no significant difference
Table 2. TB drug resistance patterns for HRZES and their distribution among TB cases in Germany, 2008–2017
(N = 3,324). Please note that MDR-TB patterns are in grey.
H R Z E S Number of cases Percentage of cases
x 816 24.6%
x 769 23.1%
x x 551 16.6%
x 412 12.4%
x x x x x 218 6.6%
x x x 112 3.4%
x 70 2.1%
x x x x 67 2.0%
x x x x 65 2.0%
x x 54 1.6%
x x x 36 1.1%
x x 27 0.8%
x x x 24 0.7%
x x x 19 0.6%
x 13 0.4%
x x x x 12 0.4%
x x x x 11 0.3%
x x x 10 0.3%
x x 10 0.3%
x x 5 0.2%
x x 5 0.2%
x x 5 0.2%
x x 3 0.1%
x x 3 0.1%
x x x x 2 0.1%
x x x 2 0.1%
x x 2 0.1%
x x x 1 0.0%
x x x 0 0.0%
x x x 0 0.0%
x x x 0 0.0%
https://doi.org/10.1371/journal.pone.0217597.t002
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between pulmonary TB cases (2,646/21,254, 13.6%) and extrapulmonary TB cases (671/4,941,
12.4%, p>0.01). For monoresistances, however, cases with pulmonary TB had a significantly
lower proportion of Z monoresistance (pulmonary: 263/2,646, 9.9%; extrapulmonary: 148/
671, 22.1%, p<0.01). In contrast, cases with pulmonary TB had a higher occurrence of MDR-
TB with 493/21,254 (2.3%) in comparison to 62/4,941 (1.3%) of cases with extrapulmonary TB
(p<0.01). Full resistance against HRZES was once again predominant among MDR-TB cases,
being reported in 196/496 (39.8%) of pulmonary MDR-TB cases and 22/62 (35.5%) of extra-
pulmonary MDR-TB cases.
Regression analyses
The final multivariable logistic regression results are presented in Table 6. Compared to adults,
children had higher odds of having any drug resistance (OR = 1.59; 95% CI: 1.27, 1.97),
MDR-TB (OR = 1.74; 95% CI: 1.03, 2.77), and resistance against all five drugs (OR = 2.08; 95%
CI: 1.24, 4.42). In contrast, elderly had lower odds for all three resistance patterns compared to
adults. Males had significantly lower odds of having any resistance in comparison to female
cases (OR = 0.90; 95% CI: 0.84,0.98), but no significant effect of sex could be found for
MDR-TB and resistance against all five drugs. Cases born outside of Germany had almost
twice the odds of having any resistance versus cases born in Germany (OR = 2.04; 95% CI:
1.87,2.22). This increased to almost 4.5 times higher odds for having MDR-TB (OR = 4.4.71;
95% CI: 3.70,6.10) and a more than 3 times higher odds for having resistance against all five
drugs (OR = 3.86; 95% CI: 2.51,6.22). Cases with prior TB diagnosis had approximately double
the odds of having any resistance versus those with no prior TB diagnosis (OR = 1.95; 95% CI:
1.76,2.16); this increased to almost 6 times higher odds for MDR-TB (OR = 5.95; 95% CI:
5.00,7.06) and 9 times higher odds for resistance against all five drugs (OR = 9.01; 95% CI:
6.66,12.19). Lastly, cases with pulmonary TB had twice the odds of having both MDR-TB
(OR = 2.00; 95% CI = 1.57,2.61) and resistance against all five drugs (OR = 2.12; 95% CI:
1.33,3.60) versus cases with extrapulmonary TB.
Discussion
Our study is one of the limited number of recent studies worldwide to analyze national surveil-
lance data on drug resistance patterns over a long period of time. Our analysis revealed an
Table 3. Proportions of any drug resistance, any H resistance, any R resistance, and MDR-TB for the 10 countries of birth with highest notifications of drug resis-
tant cases, ordered by total number of cases with any drug resistance (2008–2017).
Number of cases Any drug resistance Any H resistance Any R resistance MDR-TB
N % N % N % N %
Germany 10,969 913 8.3% 435 4.0% 96 0.9% 70 0.6%
Russia 810 269 33.2% 224 27.7% 120 14.8% 114 14.1%
Somalia 916 165 18.0% 109 11.9% 42 4.6% 35 3.8%
Kazakhstan 562 162 28.8% 136 24.2% 46 8.2% 46 8.2%
Turkey 1,269 148 11.7% 91 7.2% 6 0.5% 5 0.4%
India 816 109 13.4% 71 8.7% 20 2.5% 19 2.3%
Vietnam 389 104 26.7% 60 15.4% 9 2.3% 7 1.8%
Romania 899 103 11.5% 69 7.7% 36 4.0% 26 2.9%
Eritrea 668 98 14.7% 55 8.2% 12 1.8% 10 1.5%
Pakistan 530 94 17.7% 44 8.3% 9 1.7% 8 1.5%
Afghanistan 507 70 13.8% 40 7.9% 7 1.4% 5 1.0%
Total 18,335 2,235 12.2% 1,334 7.3% 403 2.2% 345 1.9%
https://doi.org/10.1371/journal.pone.0217597.t003
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overall any drug resistance proportion of 12.7% in Germany, among which four resistance pat-
terns were clearly predominant and accounted for more than ¾ of all drug resistant cases in–
monoresistance against S, monoresistance against H, combined resistance against HS and
monoresistance against Z. Monoresistance against S was the most prevalent drug resistance
pattern in cases born in Germany and outside Germany, as well as among all age groups, very
likely due to the long historical usage. These findings confirm that the withdrawal of S as a
first-line drug in 2012 in Germany [38] has minimal relevance for TB therapy due to high
resistance levels against it in the population. As a result, it can be questioned whether system-
atic surveillance of S resistance is still essential.
Resistance against H presents another highly prominent drug resistance pattern among
tuberculosis patients in Germany. Our analysis showed high proportions of H resistance
among all subpopulations, but cases originating from Eastern Europe showed remarkably high
proportions of resistance. This supports the use of either 3–4 months of combined H and R
therapy or 4 months of R monotherapy for LTBI treatment in Germany [19].
Table 4. The 4 predominant patterns in drug-resistant culture positive TB cases with DST results, by country of birth and age group (for cases with available infor-
mation), Germany 2008–2017, Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Ethambutol (E), and Streptomycin (S).
Age group: < 15 yr.
Country of birth Total No. of TB cases Any resistance present Among any resistance
H Z S HS
Germany 366 64 (17.5%) 16 (25.0%) 6 (9.4%) 20 (31.3%) 12 (18.8%)
Other 209 39 (18.7%) 9 (23.1%) 6 (15.4%) 7 (17.9%) 5 (12.8%)
Total 575 103 (17.9%) 25 (24.3%) 12 (11.7%) 27 (26.2%) 17 (16.5%)
Age group: 15–39 yr.
Total No. of TB cases Any resistance present Among any resistance
H Z S HS
Germany 1,979 167 (8.4%) 50 (29.9%) 10 (6.0%) 54 (32.3%) 24 (14.4%)
Other 8,323 1,381 (16.6%) 302 (21.9%) 101 (7.3%) 354 (25.6%) 218 (15.8%)
Total 10,302 1,548 (15.0%) 352 (22.7%) 111 (7.2%) 408 (26.4%) 242 (15.6%)
Age group: 40–59 yr.
Total No. of TB cases Any resistance present Among any resistance
H Z S HS
Germany 3,449 287 (8.3%) 71 (24.7%) 45 (15.7%) 76 (26.5%) 45 (15.7%)
Other 3,542 633 (17.9%) 132 (20.9%) 46 (7.3%) 139 (22.0%) 150 (23.7%)
Total 6,991 920 (13.2%) 203 (22.1%) 91 (9.9%) 215 (23.4%) 195 (21.2%)
Age group: 60+ yr.
Total No. of TB cases Any resistance present Among any resistance
H Z S HS
Germany 5,174 395 (7.6%) 91 (23.0%) 145 (36.7%) 86 (21.8%) 18 (4.6%)
Other 2,525 283 (11.2%) 78 (27.6%) 44 (15.5%) 61 (21.6%) 56 (19.8%)
Total 7,699 678 (8.8%) 169 (24.9%) 189 (27.9%) 147 (21.7%) 74 (10.9%)
All age groups
Total No. of TB cases Any resistance present Among any resistance
H Z S HS
Germany 10,969 913 (8.3%) 228 (24.9%) 206 (22.6%) 236 (25.8%) 99 (10.8%)
Other 14,600 2,336 (16.0%) 521 (22.3%) 197 (8.4%) 561 (24.0%) 429 (18.4%)
Total 25,569 3,249 (12.7%) 749 (23.1%) 403 (12.4%) 797 (24.5%) 528 (16.3%)
https://doi.org/10.1371/journal.pone.0217597.t004
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We also found unexpectedly high proportions of S and H resistances among children. A
potential explanation for this finding might be the presence of selection bias as bacteriological
confirmation is challenging in paucibacillary childhood TB and diagnosis may, as a result, be
intensified particularly in children with unknown infection sources and suspected drug
resistance.
Z monoresistance was another significant finding in our analysis. We saw a remarkably
high proportion of Z resistance among the German-born elderly population (60+), being
almost 2.5-times higher than the proportion in the foreign-born elderly. One hypothesis might
be that elderly cases present higher proportions of prior, agriculturally-acquired infection with
Mycobacterium bovis, which is inherently resistant to Z. In fact, of the 145 German-born
elderly cases with monoresistance to Z, 95 (65.5%) were reported as having M. bovis as the spe-
cies of infection. Apart from that, Z-monoresistance was 2.2-times higher in extrapulmonary
cases in comparison to pulmonary cases. Some studies have previously indicated that infection
with M. bovis more often leads to extrapulmonary TB disease [40, 41]. As a result, species
Table 5. Multidrug resistance patterns in drug-resistant culture positive TB cases with DST results, by country of birth and age group (for cases with available infor-
mation), Germany 2008–2017, Isoniazid/H, Rifampicin/R, Pyrazinamide/Z, Ethambutol/E, and Streptomycin/S.
Age group: < 15 yr.
Country of birth Total No. of TB cases MDR-TB present HR only 3 drugs 4 drugs All 5 drugs
N % N N N N
Germany 366 6 1.6% 0 2 2 2
Other 209 8 3.8% 1 1 2 4
Total 575 14 2.4% 1 3 4 6
Age group: 15–39 yr.
Total No. of TB cases MDR-TB present HR only 3 drugs 4 drugs All 5 drugs
N % N N N N
Germany 1,979 19 1.0% 2 6 3 8
Other 8,323 318 3.8% 27 71 79 141
Total 10,302 337 3.3% 29 77 82 149
Age group: 40–59 yr.
Total No. of TB cases MDR-TB present HR only 3 drugs 4 drugs All 5 drugs
N % N N N N
Germany 3,449 29 0.8% 5 10 7 7
Other 3,542 122 3.4% 11 36 33 42
Total 6,991 151 2.2% 16 46 40 49
Age group: 60+ yr.
Total No. of TB cases MDR-TB present HR only 3 drugs 4 drugs All 5 drugs
N % N N N N
Germany 5,174 16 0.3% 3 1 6 6
Other 2,525 30 1.2% 5 12 9 4
Total 7,699 46 0.6% 8 13 15 10
All age groups
Total No. of TB cases MDR-TB present HR only 3 drugs 4 drugs All 5 drugs
N % N N N N
Germany 10,969 70 0.6% 10 19 18 23
Other 14,600 478 3.3% 44 120 123 191
Total 25,569 548 2.1% 54 139 141 214
https://doi.org/10.1371/journal.pone.0217597.t005
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specification of TB infection is an important step to support appropriate design of treatment
regimens.
Between 2008 and 2017, 2.1% of all cases in Germany had MDR-TB. In comparison to the
European average of 3.7% in 2016, Germany presents a low proportion of MDR-TB cases [7].
Nevertheless, in contrast to the European-wide trend [7], we observed a slight increase in
MDR-TB cases notified over the last 10 years, the reasons for which are likely the increase in
migration from high MDR-burden regions, but perhaps also better reporting by local health
authorities. Especially of note is that we rarely observed “simple” MDR-TB, i.e. resistance to
only H and R and MDR-TB cases mostly presented additional drug resistances. Approximately
40% of MDR-TB cases in our study were resistant to all 5 drugs (HRZES) and only 10% were
resistant to H and R only. This supports the WHO recommendation to initiate MDR-TB treat-
ment with four second-line anti-TB drugs and not to rely on any first-line drugs, until detailed
DST results are available [18].
Cases with prior TB disease and foreign-born cases have a high risk of MDR-TB. Our analy-
sis showed that cases with prior TB diagnosis had an almost six times higher odds of having
MDR-TB and nine times higher odds of having resistance against all five drugs in comparison
to new cases. A number of studies have analyzed risk factors associated with MDR-TB [42–53]
for different populations around the world. All of them found prior treatment to be one of the
most significant and consistent predictors for the presence of drug resistance. In our study,
although we utilized prior TB diagnosis as a proxy for prior TB treatment, our results are con-
sistent with these previous results. Nevertheless, MDR-TB, and especially resistance against all
five drugs, was also prevalent in new cases and in children, confirming that MDR-TB strains
are endemic in many settings and that MDR-TB is no longer only a matter of acquired drug
resistance.
Cases born outside Germany had a 5.5-fold higher proportion of MDR-TB in comparison
to cases born in Germany. Several studies have also found higher proportions of MDR-TB
among migrants in comparison to the local populations [44, 47, 48, 50, 51]. Cases from Eastern
Table 6. Results of multivariable logistic regression analysis of factors associated with any drug resistance (HRESZ), multidrug resistant TB, and resistance against
all five drugs (HRESZ), 2008–2017.
Risk factor Any drug resistance Multidrug resistance (MDR-TB) Resistance against all five drugs (HRZES)
OR 95% CI OR 95% CI OR 95% CI
lower upper lower upper lower upper
Age (years)
Adult (<15) ref ref ref
Child (15–59) 1.59 1.27 1.97 1.74 1.03 2.77 2.02 0.78 4.30
Elderly (60+) 0.64 0.58 0.70 0.24 0.18 0.32 0.12 0.05 0.23
Sex
Female ref ref ref
Male 0.90 0.84 0.98 0.95 0.80 1.13 0.81 0.60 1.11
Country of birth
Germany ref ref ref
Not Germany 2.04 1.87 2.22 4.71 3.70 6.10 3.85 2.50 6.20
Prior TB
No ref ref ref
Yes 1.95 1.76 2.16 5.95 5.00 7.06 9.06 6.66 12.26
Main site of TB
Extrapulmonary ref ref ref
Pulmonary 0.98 0.89 1.07 2.00 1.57 2.61 2.17 1.36 3.69
https://doi.org/10.1371/journal.pone.0217597.t006
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Europe, especially Russia and Kazakhstan, accounted for a substantial proportion of cases with
MDR-TB in our study. This is in line with findings from Falzon and colleagues [50] showing
that MDR-TB is strongly associated with origin from the former Soviet countries. Surveillance
figures further show that Eastern European countries account for 85% of the TB burden and
99% of the MDR-TB cases in the WHO European region [9, 50]. However, due to the arrival
of a substantial number of refugees and asylum seekers into Germany from 2014–2016, the
migration pattern in Germany has undergone a changed. For example, African countries,
among them countries with a high burden of drug resistant TB, such as Somalia and Eritrea,
have recently become prominent in the drug resistance landscape, accounting for a consider-
able proportion of drug resistant cases. Between 2013 and 2017, cases from Somalia and Eritrea
accounted for 11.2% and 7.2%, respectively, of all foreign-born cases with any resistance
(2008–2013: 2.3% and 0.7%) and for 10.9% and 2.9% of all foreign-born MDR-TB cases
(2008–2013: 1.0% for both). MDR-TB cases from countries in the Horn of Africa, such as
Somalia and Eritrea, were also the subject of a large Europe-wide outbreak investigation in
2016, where the majority of the cases in the cluster were reported in Germany [54]. Neverthe-
less, the overall proportion of MDR TB remained stable at 2–3%, and we also found MDR-TB
in cases born in Germany, especially among younger, German-born cases, which highlights
the continued need for rapid DST and strengthened bacteriological confirmation among all
age groups.
Rapid DST techniques are meaningful, especially in patients with high risk of drug-resistant
TB, in order to rapidly commence adequate treatment before phenotypic DST results become
available. Recently, R resistance has increasingly been considered as a surrogate marker for
MDR-TB [23]. Although R monoresistance is rare worldwide [38], it seems to be prevalent in
Germany. 13.5% of R-resistant cases in our study did not have H-resistance and among those
without accompanying H-resistance, about 80% of all R-resistant cases were monoresistant.
Together with the high proportion of H resistance in Germany and our finding that
MDR-TB is rarely only HR resistance in Germany, our results raise some concerns about the
possibility of incorrect diagnosis of drug-resistant TB in Germany if currently available rapid
tests were to be used as the only diagnostic tests. Focusing on only R resistance or HR resis-
tance, other important and relevant resistance patterns would be overlooked unless additional
testing is conducted [55]. Although more resource-intensive, comprehensive genotypic testing
using whole genome sequencing has shown high concordance with conventional phenotypic
techniques for first line TB drugs and could, therefore, be another relevant rapid test technol-
ogy in resource-rich countries in the future [55].
In our multivariable regression analyses, we found that being born outside of Germany and
prior TB disease diagnosis were the only consistent risk factors associated with having any
resistance, MDR-TB, and complete first-line resistance. In line with our findings, most studies
do not report any significant association between sex and MDR-TB [42, 43, 45, 56, 57]. Never-
theless, Faustini, Hall and Perucci [44] report male sex to be a risk factor, while Liu et. al. [52]
found an association between female sex and MDR-TB. Several other studies have found youn-
ger age to be associated with the development of MDR-TB [44, 46, 49, 52, 53]. We could not
support these findings with the results from our multivariable analysis, but results from our
descriptive analysis indicate a similar pattern.
Our study has a number of limitations. Our study is based on reported surveillance data
and we did not have insight into the original laboratory results or into detailed DST informa-
tion on the cases. Because our data includes a considerable number of migrant cases, who can
be a mobile population group, our surveillance data is incomplete for a number of variables,
especially on DST. Of the 48,044 notified active TB cases between 2008 and 2017 in Germany,
76.8% had DST results available for HRZES. Although this is above the European average,
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notified DST testing rates in Germany do not meet ECDC’s target for TB elimination [7].
According to the ECDC, performing cultures and DST in at least 80% of the cases is a neces-
sary step to achieve the elimination of TB in Europe [58].As a result, our lower DST testing
coverage should be interpreted with caution. Moreover, DST for E and Z are less reliable than
DST for H and R, especially in MDR-TB cases. Information on resistance against second-line
drugs is limited and could therefore not be included in our analysis. Information on social
determinants and behavioural risk factors such as HIV status, unemployment, alcohol and
drug abuse, smoking, and diabetes is not reported at the national level of the the notification
system and could also not be included in the risk factor analysis. Since data on prior treatment
was incomplete, we utilized prior TB diagnosis as proxy, but this may mean that we may have
missed relevant information on the type of prior treatment and its outcome.
Conclusion
Drug resistance patterns observed in Germany, particularly for MDR-TB cases, are far more
complex than expected. Although the overall proportions of drug-resistance and MDR-TB are
low, most MDR-TB cases in Germany present with additional resistances against other stan-
dard anti-TB drugs and almost 40% of MDR cases showed complete resistance against all five
standard TB drugs (HRZES). As drug resistance patterns vary significantly in different sub-
groups, our findings highlight the importance of considering demographic characteristics of
cases and knowing the patients’ full drug resistance profile to tailor treatment for optimal out-
come. This is especially significant as our study found higher than expected proportions of
drug resistances and MDR-TB among children and German-born adults. Finally, our finding
of considerably high H monoresistance rates is important towards informing LTBI treatment
regimens in Germany.
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34. Robert Koch Institut. Leitfaden zur Übermittlung von Fallberichten zur Tuberkulose. Berlin: Robert
Koch Institut; 2004.
35. Hoffner S. Unexpected high levels of multidrug-resistant tuberculosis present new challenges for tuber-
culosis control. Lancet (London, England). 2012; 380(9851):1367–9.
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